Patents by Inventor Akinori CHIKUSHI

Akinori CHIKUSHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY
    Publication number: 20230398213
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 14, 2023
    Applicant: UPSTREAM BIO, INC.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • Pharmaceutical composition comprising anti-human TSLP receptor antibody
    Patent number: 11712472
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: August 1, 2023
    Assignee: Upstream Bio, Inc.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY
    Publication number: 20220023422
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Application
    Filed: February 10, 2021
    Publication date: January 27, 2022
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Megumi IKEDA, Akinori CHIKUSHI
  • Pharmaceutical composition comprising anti-human TSLP receptor antibody
    Patent number: 10994011
    Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 4, 2021
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • PHARMACEUTICAL COMPOSITION COMPRISING PEGYLATED FAB' FRAGMENT OF ANTI-HUMAN NGF ANTIBODY
    Publication number: 20200299371
    Abstract: Provided is a stable pharmaceutical composition comprising a PEGylated Fab? fragment of an anti-human NGF antibody, capable of inhibiting the formation of degradation products, multimers, acidic related substances, basic related substances, and insoluble foreign substances. The pharmaceutical composition has a pH of 4 to 5.5, and can further comprise a pharmaceutically acceptable buffer, a pharmaceutically acceptable isotonizing agent, and a pharmaceutically acceptable surfactant, if desired.
    Type: Application
    Filed: March 24, 2017
    Publication date: September 24, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Ayano YAMAMOTO, Akinori CHIKUSHI
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY
    Publication number: 20190111129
    Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 18, 2019
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Megumi IKEDA, Akinori CHIKUSHI